Centrifugal pump and heparin coating improves cardiopulmonary bypass biocompatibility

Moen, Oddvar; Fosse, Erik; Dregelid, Einar; Brockmeier, Vibeke; Andersson, Conny; Høgåsen, K; Venge, Per; Mollnes, Tom Eirik; Kierulf, Peter

doi:10.1016/0003-4975(96)00492-4

Cited by 84 publications

(40 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The PMP oxygenators require less red blood cell and platelet transfusions, provide better gas exchange, have lower resistance and priming volumes compared to silicone membrane oxygenators and have less oxygenator failure compared to polypropylene microporous oxygenators [26]. The development of heparin-coated circuits has made a significant impact with less platelet, complement, and granulocyte activation with reduced heparin requirements [27,28]. Another important advancement was the development of new generation centrifugal pumps that have essentially no risk of tubing rupture with a smaller priming volume and no need for a reservoir [29].…”

Section: Discussionmentioning

confidence: 98%

Ambulatory venovenous extracorporeal respiratory support as a bridge for cystic fibrosis patients to emergent lung transplantation

Hayes

Kukreja²,

Tobias

et al. 2012

Journal of Cystic Fibrosis

View full text Add to dashboard Cite

Venovenous extracorporeal membrane oxygenation (VV ECMO) is a therapeutic option to bridge patients with advanced lung disease to lung transplantation. The use of VV ECMO avoids the use of mechanical ventilation while allowing patients to participate in physical therapy and to eat normally while receiving respiratory support. We describe the successful use of ambulatory single-venous VV ECMO as a bridge to bilateral lung transplantation in 4 patients with end-stage lung disease due to cystic fibrosis who developed acute hypercapnic respiratory failure. The use of ambulatory single-venous VV ECMO was safe and effective in this small cohort of CF patients. Based on our experiences, our belief is that a key step in the treatment course was early application of VV ECMO soon after development of acute respiratory failure requiring mechanical ventilation.

show abstract

Section: Discussionmentioning

confidence: 98%

Ambulatory venovenous extracorporeal respiratory support as a bridge for cystic fibrosis patients to emergent lung transplantation

Hayes

Kukreja²,

Tobias

et al. 2012

Journal of Cystic Fibrosis

View full text Add to dashboard Cite

show abstract

“…15,16 Importantly, PMP oxygenators can be readily heparin coated, whereas the silicone membrane oxygenators cannot. Thus, a modern ECMO circuit can be entirely heparin coated and requires minimal systemic heparinization.…”

Section: Discussionmentioning

confidence: 99%

Use of Extracorporeal Membrane Oxygenation as a Bridge to Primary Lung Transplant: 3 Consecutive, Successful Cases and a Review of the Literature

Jackson

Cropper

Pye

et al. 2008

The Journal of Heart and Lung Transplantation

102

View full text Add to dashboard Cite

“…Hence, determination of plasma levels of TF serves as a marker for extrinsic pathway activation of coagulation. Since a better blood handling of the centrifugal pump as compared with the roller pump has been proposed in earlier studies [13,19], it can be assumed that the use of a centrifugal pump will result in a lower release of TF. Indeed, we observed lower TF release (area under the curve) in the group where a centrifugal pump was applied, thus proving the hypothesis of our study.…”

Section: Discussionmentioning

confidence: 99%

“…Activation of coagulation during CPB may be caused either by contact activation (intrinsic pathway) or by tissue or blood cell damage (extrinsic pathway). The activation of coagulation via the extrinsic pathway might be reduced by the application of a centrifugal pump which has been shown to cause less blood cell damage compared with the conventional roller pump [2,13]. Activation of the extrinsic pathway can be differentiated from activation of the intrinsic pathway of coagulation by analyzing the levels of tissue factor (TF, procoagulant activity).…”

Section: Introductionmentioning

confidence: 99%

Reduced release of tissue factor by application of a centrifugal pump during cardiopulmonary bypass

et al. 1998

View full text Add to dashboard Cite

The application of a centrifugal pump might lead to a reduced release of tissue factor (TF) due to less blood cell damage. This could result in a decrease in activation of the extrinsic pathway of coagulation and embolus formation. In the present study, 60 patients undergoing coronary artery bypass grafting were randomly assigned to a centrifugal or a roller pump. Plasma concentrations of TF, thrombin-antithrombin complex (TAT), and prothrombin fragments F1 + 2 were investigated before, during, and after cardiopulmonary bypass (CPB). Embolus detection was performed at the arterial line of CPB and transcranially by Doppler ultrasound. The centrifugal pump group revealed a lower TF release (area under the curve during CPB) when compared with the roller pump group [5661 (696-10359) vs 12681 (6383-17538) microg x min/l; median (lower - upper quartiles); P = 0.009]. In contrast, TAT and F1 + 2 formation did not differ between the groups, and neither did the total embolus count of both Doppler systems. Embolus counts did not correlate with TAT or F1 + 2 formation. In conclusion, the reduction in TF release by the application of a centrifugal pump seems to have little consequence on total thrombin formation. Since the applied Doppler systems seem to detect mainly microbubbles, conclusions regarding differences between the two pumps in the formation of thrombofibrinous clots cannot be drawn.

show abstract

Centrifugal pump and heparin coating improves cardiopulmonary bypass biocompatibility

Cited by 84 publications

References 21 publications

Ambulatory venovenous extracorporeal respiratory support as a bridge for cystic fibrosis patients to emergent lung transplantation

Ambulatory venovenous extracorporeal respiratory support as a bridge for cystic fibrosis patients to emergent lung transplantation

Use of Extracorporeal Membrane Oxygenation as a Bridge to Primary Lung Transplant: 3 Consecutive, Successful Cases and a Review of the Literature

Reduced release of tissue factor by application of a centrifugal pump during cardiopulmonary bypass

Contact Info

Product

Resources

About